APA (7th ed.) Citation

G, K., MU, M., LS, M., M, M., J, A., L, B., . . . JF, D. (2025). Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). JCO precision oncology, 9, e2500556. https://doi.org/10.1200/PO-25-00556

Chicago Style (17th ed.) Citation

G, Koehne, et al. "Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)." JCO Precision Oncology 9 (2025): e2500556. https://doi.org/10.1200/PO-25-00556.

MLA (9th ed.) Citation

G, Koehne, et al. "Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)." JCO Precision Oncology, vol. 9, 2025, p. e2500556, https://doi.org/10.1200/PO-25-00556.